文献速递乳腺癌

新辅助度伐利尤单抗改善早期三阴性乳腺癌生存且不依赖病理完全缓解

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.
PubMed 文献 · Ann Oncol · 2022-08-09

GeparNuevo试验纳入174例早期三阴性乳腺癌患者,随机接受新辅助化疗联合度伐利尤单抗或安慰剂,术后不继续度伐利尤单抗。中位随访43.7个月,度伐利尤单抗组3年无侵袭性疾病生存、无远处疾病生存和总生存均显著优于安慰剂组,且多因素分析证实其疗效独立于病理完全缓解。

要点

  • 度伐利尤单抗组3年iDFS为85.6%,安慰剂组为77.2%(HR 0.48,95%CI 0.24-0.97,P=0.036)。
  • 度伐利尤单抗组3年OS为95.2%,安慰剂组为83.5%(HR 0.24,95%CI 0.08-0.72,P=0.006)。
  • 多因素分析证实度伐利尤单抗的生存获益独立于病理完全缓解效应。

核心结论

  • 在新辅助化疗中加入度伐利尤单抗可显著改善三阴性乳腺癌患者的生存,尽管病理完全缓解率仅中度增加且术后未继续使用度伐利尤单抗。
  • 原文结论指出需要额外研究来明确早期三阴性乳腺癌中检查点抑制剂的最佳疗程和顺序。

研究设计与样本

  • GeparNuevo(NCT02685059)试验为随机对照研究,2016年6月至2017年10月共随机分配174例cT1b-cT4a-d三阴性乳腺癌患者。
  • 患者接受度伐利尤单抗1.5 g或安慰剂每4周一次,联合白蛋白结合型紫杉醇125 mg/m2每周一次共12周,随后度伐利尤单抗/安慰剂每4周联合表柔比星/环磷酰胺每2周,之后手术;术后不继续度伐利尤单抗。
  • 主要目标为病理完全缓解率,次要终点包括无侵袭性疾病生存、无远处疾病生存和总生存。

主要发现

  • 中位随访43.7个月,共发生34例事件。
  • 度伐利尤单抗组3年无侵袭性疾病生存为85.6%,安慰剂组为77.2%(HR 0.48,95%CI 0.24-0.97,分层log-rank P=0.036)。
  • 度伐利尤单抗组3年无远处疾病生存为91.7%,安慰剂组为78.4%(HR 0.31,95%CI 0.13-0.74,P=0.005)。
  • 度伐利尤单抗组3年总生存为95.2%,安慰剂组为83.5%(HR 0.24,95%CI 0.08-0.72,P=0.006)。
  • 病理完全缓解患者中,度伐利尤单抗组3年无侵袭性疾病生存为95.5%,无度伐利尤单抗组为86.1%(HR 0.22,95%CI 0.05-1.06);非病理完全缓解队列中分别为76.3%和69.7%(HR 0.67,95%CI 0.29-1.54)。

关键数值与推荐

  • 既往报道显示,在新辅助化疗中加入度伐利尤单抗使病理完全缓解率绝对增加9%(P=0.287)。
  • 多因素分析证实度伐利尤单抗疗效独立于病理完全缓解效应。
  • 未出现新的安全性信号。

局限性

  • 原文结论指出需要额外研究来明确早期三阴性乳腺癌中检查点抑制剂的最佳疗程和顺序。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Addition of immune checkpoint inhibitors to neoadjuvant chemotherapy (NACT) is a promising strategy in early breast cancer, but the optimal duration of therapy is currently unknown. In the GeparNuevo (NCT02685059) trial, addition of durvalumab to NACT as previously reported led to a moderate increase in pathological complete response (pCR) rate by an absolute 9% (P = 0.287). PATIENTS AND METHODS: Patients with cT1b-cT4a-d triple-negative breast cancer (TNBC) received durvalumab 1.5 g or placebo every 4 weeks added to nab-paclitaxel 125 mg/m2 weekly for 12 weeks, followed by durvalumab/placebo every 4 weeks plus epirubicin/cyclophosphamide every 2 weeks followed by surgery. Durvalumab was not continued after surgery. The primary objective was pCR. Secondary endpoints included invasive disease-free survival (iDFS), distant disease-free survival (DDFS) and overall survival (OS). RESULTS: A total of 174 patients were randomised between June 2016 and October 2017. After a median follow-up of 43.7 months, 34 events had occurred. Despite a non-significant increase in the pCR rate, significant differences were observed for 3-year iDFS, DDFS and OS: iDFS was 85.6% with durvalumab versus 77.2% with placebo [hazard ratio (HR) 0.48, 95% confidence interval (CI) 0.24-0.97, stratified log-rank P = 0.036]; DDFS 91.7% versus 78.4% (HR 0.31, 95% CI 0.13-0.74, P = 0.005); OS 95.2% versus 83.5% (HR 0.24, 95% CI 0.08-0.72, P = 0.006). pCR patients had 3-year iDFS of 95.5% with durvalumab and 86.1% without (HR 0.22, 95% CI 0.05-1.06). In the non-pCR cohort 3-year iDFS was 76.3% versus 69.7% (HR 0.67, 95% CI 0.29-1.54). Multivariable analysis confirmed a durvalumab effect independent of the pCR effect. No new safety signals occurred. CONCLUSIONS: Durvalumab added to NACT in TNBC significantly improved survival despite a modest pCR increase and no adjuvant component of durvalumab. Additional studies are needed to clarify the optimal duration and sequence of checkpoint inhibitors in the treatment of early TNBC.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Loibl S, Schneeweiss A, Huober J, et al. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. Ann Oncol. 2022. PMID: 35961599. doi:10.1016/j.annonc.2022.07.1940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。